<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-7459</journal-id>
<journal-title><![CDATA[Horizonte sanitario]]></journal-title>
<abbrev-journal-title><![CDATA[Horiz. sanitario]]></abbrev-journal-title>
<issn>2007-7459</issn>
<publisher>
<publisher-name><![CDATA[Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-74592022000200204</article-id>
<article-id pub-id-type="doi">10.19136/hs.a21n2.4672</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Costo-efectividad del tratamiento de diabetes tipo 2 en primer nivel de atención]]></article-title>
<article-title xml:lang="en"><![CDATA[Cost Effectiveness of type 2 diabetes treatment at first level of care]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Figueroa-Gaspar]]></surname>
<given-names><![CDATA[Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marín-Mendoza]]></surname>
<given-names><![CDATA[Eréndira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chávez-Briseño]]></surname>
<given-names><![CDATA[Érika]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arredondo]]></surname>
<given-names><![CDATA[Armando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[Cuernavaca Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[Cuernavaca Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[Cuernavaca Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[Cuernavaca Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2022</year>
</pub-date>
<volume>21</volume>
<numero>2</numero>
<fpage>204</fpage>
<lpage>213</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-74592022000200204&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-74592022000200204&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-74592022000200204&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Objetivo: Identificar el mejor tratamiento costo-efectividad para la diabetes tipo 2 en pacientes ambulatorios, de los tres principales esquemas de tratamiento en una unidad de atención de primer nivel en el estado de Morelos, México.  Material y Métodos: En una muestra de 1,795 pacientes atendidos en una unidad de primer nivel, se realizó el cálculo del coeficiente de costo- efectividad para tres esquemas de tratamiento, seleccionados como parte del tratamiento escalonado sugerido en las guías principales y por su disponibilidad en el primer nivel de atención. Los costos de cada intervención se calcularon utilizando el método de estimación de instrumentación y la técnica de manejo de caso promedio. Se realizó una búsqueda en bases de datos PubMed, Scopus, Scielo y Latindex con base en palabras clave, y se hizo una revisión de la literatura donde se evaluó la eficacia de los esquemas de tratamiento de interés y la efectividad se determinó a partir de la reacción de los fármacos de cada intervención, en comparación con los efectos de la dieta y otros hipoglucemiantes. Para identificar la regla de decisión, se determinó el coeficiente de costo-efectividad de cada intervención.  Resultados: La mejor intervención costo-efectividad se basó en un tratamiento oral combinado de metformina con glibenclamida, obteniendo un costo total de $ 951.75 USD, con una tasa de efectividad del 42.30% y un coeficiente de efectividad de 2.25.  Conclusiones: Para el primer nivel de atención, se recomienda promover más el uso del tratamiento oral combinado de metformina con glibenclamida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Objective: To identify the most cost-effective treatment in three main schemes for type 2 diabetes mellitus outpatients in a first level care unit in the Morelos State.  Materials and Method: In a sample of 1795 patients treated in a first-level unit, the cost-effectiveness coefficient calculation was performed for three treatment schemes, selected as part of the stepped treatment suggested in the main guides and for their availability at the first level of care. Costs of each intervention were calculated using the instrumentation estimation method and the average case management technique. A search was carried out in PubMed, Scopus, Scielo and Latindex databases based on keywords, and a review of the literature was made where the efficacy of the treatment schemes of interest was evaluated and the effectiveness was determined from the effect of the drugs of each intervention, compared to the effects of diet and other hypoglycemics. To identify the decision rule, the cost- effectiveness coefficient of each intervention was determined.  Results: The most cost-effective intervention was based on a combined oral treatment of metformin with glibenclamide, obtaining a total cost of $951.75 USD, with an effectiveness rate of 42.30% and an effectiveness coefficient of 2.25.  Conclusions: For the first level of care, it is recommended to promote more the use of combined oral treatment of metformin with glibenclamide.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Costo Efectividad]]></kwd>
<kwd lng="es"><![CDATA[Tratamiento Farmacológico]]></kwd>
<kwd lng="es"><![CDATA[Diabetes Mellitus]]></kwd>
<kwd lng="es"><![CDATA[Atención Primaria de Salud]]></kwd>
<kwd lng="en"><![CDATA[Cost Effectiveness]]></kwd>
<kwd lng="en"><![CDATA[Drug Therapy]]></kwd>
<kwd lng="en"><![CDATA[Diabetes Mellitus]]></kwd>
<kwd lng="en"><![CDATA[Primary Health Care]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brutsaert]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes mellitus (DM) - Trastornos endocrinológicos y metabólicos [Internet]. Manual MSD]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rull]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Salinas]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rios-Torres]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Pérez]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Olaiz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of type 2 diabetes in Mexico]]></article-title>
<source><![CDATA[Archives of Medical Research]]></source>
<year>2005</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>188-96</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Perfiles de los países para la diabetes]]></source>
<year>2016</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Organization for Economic Cooperation and Development</collab>
<source><![CDATA[Health at a Glance 2017: OECD Indicators]]></source>
<year>2017</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>INSP</collab>
<collab>INEGI</collab>
<source><![CDATA[Encuesta Nacional de Salud y Nutrición 2018. Presentación de resultados]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agudelo-Botero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dávila-Cervantes]]></surname>
<given-names><![CDATA[CA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carga de la mortalidad por diabetes mellitus en América Latina 2000-2011: los casos de Argentina, Chile, Colombia y México]]></article-title>
<source><![CDATA[Gaceta Sanitaria]]></source>
<year>2015</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>172-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Organization for Economic Cooperation and Development</collab>
<source><![CDATA[OECD Reviews of Health Systems]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Mexico ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arredondo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aviles]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costs and Epidemiological Changes of Chronic Diseases: Implications and Challenges for Health Systems]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2015</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez Sánchez-Migallón]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control Metabólico en Pacientes Diabéticos Tipo 2: grado de Control y nivel de Conocimientos (Estudio AZUER)]]></article-title>
<source><![CDATA[Rev Clin Med Fam]]></source>
<year>2011</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>32-41</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Instituto Mexicano del Seguro Social</collab>
<source><![CDATA[Tratamiento de la Diabetes Mellitus Tipo 2 en el Primer Nivel de Atención]]></source>
<year>2014</year>
<publisher-name><![CDATA[México]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Figueroa Gaspar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Juanico Morales]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ríos Oliveros]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Calidad de la Atención Médica y su efecto sobre el Control Glucémico en Pacientes Diabéticos de la UMF No.9 del IMSS en Acapulco, Gro]]></source>
<year>2016</year>
<publisher-name><![CDATA[BUAP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mourão-Júnior]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Sá]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Guedes]]></surname>
<given-names><![CDATA[OMS]]></given-names>
</name>
<name>
<surname><![CDATA[Dib]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin]]></article-title>
<source><![CDATA[Braz J Med Biol Res]]></source>
<year>2006</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>489-94</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín Muñoz]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Muros Bayo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[González Álvaro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Costa Zamora]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformina en el tratamiento de la diabetes tipo 2 con sobrepeso u obesidad]]></article-title>
<source><![CDATA[An Med Interna]]></source>
<year>2005</year>
<volume>22</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>579-85</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camacho-Saavedra]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Soberón-Requena]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia de la glibenclamida con metformina en el control de la glicemia en pacientes con diabetes mellitus tipo 2]]></article-title>
<source><![CDATA[Rev Per Soc Med Intern]]></source>
<year>2001</year>
<volume>148</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>148-52</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas-Martínez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Basto-Abreu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Salinas]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Zárate-Rojas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Villalpando]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barrientos-Gutiérrez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of previously diagnosed diabetes mellitus in Mexico]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2018</year>
<volume>60</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>224-32</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Franch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cases]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[González Juanatey]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Conthe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relación del grado de control glucémico con las características de la diabetes y el tratamiento de la hiperglucemia en la diabetes tipo 2. Estudio DIABES]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2012</year>
<volume>138</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>505-11</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez-Hinojosa]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Zacarías-Castillo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Torres- Tamayo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tenorio-Aguirre]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Viloria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Costos económicos en el tratamiento farmacológico del paciente con diabetes mellitus tipo 2. Estudio de pacientes en consulta externa de medicina interna de un hospital de segundo nivel de la Ciudad de México]]></article-title>
<source><![CDATA[Salud Pública de México]]></source>
<year>2017</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Soto Paniagua]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Aguilar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de hipoglucemiantes orales en pacientes con diabetes mellitus tipo 2]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2005</year>
<volume>35</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>348-52</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<collab>DOF</collab>
<article-title xml:lang=""><![CDATA[NORMA OFICIAL MEXICANA NOM-178-SSA1-1998, QUE ESTABLECE LOS REQUISITOS MINIMOS DE INFRAESTRUCTURA Y EQUIPAMIENTO DE ESTABLECIMIENTOS PARA LA ATENCION MEDICA DE PACIENTES AMBULATORIOS]]></article-title>
<source><![CDATA[Diario Oficial de la Federación]]></source>
<year>1999</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<collab>DOF</collab>
<article-title xml:lang=""><![CDATA[ACUERDO ACDO.SA2.HCT.250718/195.P.DA y su Anexo Único denominado Manual de Organización del Instituto Mexicano del Seguro Social]]></article-title>
<source><![CDATA[Diario Oficial de la Federación]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<collab>Instituto Mexicano del Seguro Social</collab>
<source><![CDATA[Portal de compras del IMSS]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arredondo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Orozco]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Abis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Al]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consideraciones conceptuales sobre: costos, transición epidemiológica, financiamiento, equidad y gobernanza en salud]]></article-title>
<source><![CDATA[Temas Selectos en Sistemas de Salud: Costos, Financiamiento, Equidad y Gobernanza]]></source>
<year>2009</year>
<edition>Primera</edition>
<page-range>28-37</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Autónoma de Yucatán]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<collab>DOF</collab>
<article-title xml:lang=""><![CDATA[Parámetros de Estimación de Vida útil]]></article-title>
<source><![CDATA[Diario Oficial de la Federación]]></source>
<year>2012</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mata Cases]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformina y diabetes mellitus tipo 2]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2008</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>147-53</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas Sánchez]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Toledo Hernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherencia al tratamiento y su relación con el control metabólico en pacientes con diabetes mellitus tipo 2, en una unidad de medicina familiar en Cuernavaca, Morelos, México]]></article-title>
<source><![CDATA[Aten Fam]]></source>
<year>2018</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>146</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meltzer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Leiter]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Daneman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstein]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ludwig]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[1998 Clinical practice guidelines for the management of diabetes in Canada]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>1998</year>
<volume>159</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>S1-29</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goday]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La terapia combinada en la diabetes mellitus tipo 2]]></article-title>
<source><![CDATA[FMC]]></source>
<year>2002</year>
<volume>9</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>481-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montanya Mias]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aceptación y barreras para el inicio y la intensificación del tratamiento con insulina]]></article-title>
<source><![CDATA[Endocrinol Nutr]]></source>
<year>2007</year>
<volume>54</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>17-22</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<collab>International Diabetes Federation European Region</collab>
<source><![CDATA[A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group]]></source>
<year>1999</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[León-Castañeda]]></surname>
<given-names><![CDATA[CD de]]></given-names>
</name>
<name>
<surname><![CDATA[Altagracia-Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kravzov-Jinich]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cárdenas-Elizalde]]></surname>
<given-names><![CDATA[M del R]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno- Bonett]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Núñez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness study of oral hypoglycemic agents in the treatment of outpatients with type 2 diabetes attending a public primary care clinic in Mexico City]]></article-title>
<source><![CDATA[Clinicoecon Outcomes Res]]></source>
<year>2012</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
